| Literature DB >> 26648182 |
Hiroshi Kataoka1, Yohei Okada2, Takao Kiriyama1, Yorihiro Kita2, Junji Nakamura2, Shu Morioka2, Koji Shomoto2, Satoshi Ueno1.
Abstract
OBJECTIVE: Galvanic vestibular stimulation (GVS) activates the vestibular afferents, and these changes in vestibular input exert a strong influence on the subject's posture or standing balance. In patients with Parkinson's disease (PD), vestibular dysfunction might contribute to postural instability and gait disorders.Entities:
Keywords: Galvanic vestibular stimulation; Parkinson; Postural instability; Posture.; Vestibular dysfunction; Vestibular stimulation
Year: 2015 PMID: 26648182 PMCID: PMC4734983 DOI: 10.14802/jmd.15030
Source DB: PubMed Journal: J Mov Disord ISSN: 2005-940X
Clinical features of 5 patients with Parkinson’s disease
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|
| Age/sex | 69/F | 73/F | 66/F | 63/M | 72/F |
| Disease duration (years) | 4.5 | 7 | 14 | 10.5 | 20 |
| Hoehn-Yahr stage | 3 | 4 | 4 | 3 | 3 |
| UPDRS part 3 | 34 | 32 | 13 | 18 | 30 |
| Onset’s feature | Left tremor | Right tremor | Gait difficulty | Akinesia | Right tremor |
| History of hallucinations | - | + | - | - | + |
| History of falls | - | + | + | + | + |
| Wfearing-off | - | + | + | - | + |
| Dyskinesia | - | - | - | - | - |
| Lumbago pain | - | - | + | + | + |
| Abnormal posture | LTF | LTF | Cam | Cam | LTF |
| Duration of the abnormal posture (m) | 11 | 9 | 6.9 years | 2 years | 4 years |
| Daily treatment during the study (dose/d) | |||||
| Levodopa | 300 mg | 200 mg | 550 mg | 300 mg | 200 mg |
| Pramipexole | 1.5 mg | 1.5 mg | 3 mg | - | 1.5 mg |
| Ropinirole | - | - | - | 6 mg | - |
| Bromocriptine | - | - | 5 mg | - | - |
| Selegiline | - | - | - | 2.5 mg | - |
| Trihexyphenidyl | - | 6 mg | 2 mg | - | 6 mg |
| Amantadine | - | 150 mg | - | - | 150 mg |
| Entacapone | - | 200 mg | - | 100 mg | 200 mg |
| Zonisamide | - | - | - | 25 mg | - |
| Istradefylline | - | 40 mg | - | - | 40 mg |
| Neuroleptics | - | Rivastigmine (18 mg/d), quetiapine (12.5 mg/d) | - | - | - |
| First stimulation | Sham | GVS | GVS | GVS | Sham |
| UPDRS part 3, item 12 | |||||
| Before GVS stimulation | 3 | 3 | 3 | 3 | 3 |
| After GVS stimulation | 0 | 1 | 0 | 3 | 3 |
| Postural abnormality | |||||
| Before GVS stimulation (degree) | 5.94 | 2.31 | 49.70 | 57.49 | 5.82 |
| After GVS stimulation (degree) | 6.18 | 3.01 | 46.90 | 55.25 | 3.86 |
UPDRS: Unified Parkinson’s Disease Rating Scale, LTF: lateral trunk flexion, Cam: camptocormia, GVS: galvanic vestibular stimulation, Sham: sham stimulation, m: months, d: day.